Basilea Pharmaceutica Ltd. Logo

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

Wednesday, April 09. 2014
Basel, Switzerland, April 9, 2014 -Basilea Pharmaceutica Ltd. (SIX: BSLN) reported that at today's Ordinary General Meeting of Shareholders for the financial year 2013, shareholders approved all agenda items proposed by the Board of Directors. At the meeting, 51.3 percent of Basilea's share capital was represented.
Monday, April 07. 2014
Basel, Switzerland, April 7, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reported today that new data demonstrating the broad activity of Basilea's novel oncology drug candidate BAL101553 in pre-clinical models of human breast cancer, including models resistant to standard agents used for the treatment of breast cancer, were presented at the American Association of Cancer Research (AACR) Annual Meeting in San Diego, California, USA.
Friday, February 28. 2014
Basel, Switzerland, February 28, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the amendment as of February 27, 2014 of the isavuconazole License, Co-Development and Co-Promotion Agreement with Astellas Pharma Inc. originally executed in 2010, providing Basilea full rights to isavuconazole in all markets outside of the U.S. and Canada in return for Basilea's right to co-promote the product in the U.S. and Canada and its right to receive payments related to co-promotion and EU milestone payments.
Thursday, February 27. 2014
Basel, Switzerland, February 27, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds.

Infectious Diseases
Society of America